Skip to Content

186 Results Found

  • Article
  • Open Access
18 Citations
4,649 Views
16 Pages

25 August 2022

Enhanced quadrivalent influenza vaccines that include an adjuvant (aQIV) or a high dose of antigen (QIV-HD), which stimulate a stronger immune response in older adults than the standard vaccine (QIVe), are now approved. The objective of this research...

  • Article
  • Open Access
9 Citations
4,091 Views
12 Pages

Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain)

  • Juan J. Hernandez-Aguado,
  • Damián Ángel Sánchez Torres,
  • Esther Martínez Lamela,
  • Gema Aguión Gálvez and ,
  • Eva Sanz Espinosa,
  • Almudena Pérez Quintanilla,
  • Daniela A. Martínez-Carrillo,
  • Mar Ramírez Mena,
  • Pluvio J. Coronado Martín and
  • Jesús de la Fuente-Valero
  • + 6 authors+ 1 author

3 March 2022

A fully government-funded human papillomavirus (HPV) vaccination program started in 2007 in Spain (only 11–14-year-old girls). The first of those vaccinated cohorts, with the quadrivalent vaccine (Gardasil), turned 25 years old in 2018, the age...

(This article belongs to the Section Human Papillomavirus Vaccines)
  • Article
  • Open Access
5 Citations
2,741 Views
11 Pages

Evaluation of a Quadrivalent Shigella flexneri Serotype 2a, 3a, 6, and Shigella sonnei O-Specific Polysaccharide and IpaB MAPS Vaccine

  • Emily M. Boerth,
  • Joyce Gong,
  • Becky Roffler,
  • Zoe Hancock and ,
  • Lydia Berger,
  • Boni Song,
  • Sasha F. Malley,
  • Calman A. MacLennan,
  • Fan Zhang and
  • Ying-Jie Lu
  • + 6 authors+ 1 author

24 September 2024

Background: Shigellosis is the leading cause of diarrheal deaths worldwide and is particularly dangerous in children under 5 years of age in low- and middle-income countries. Additionally, the rise in antibiotic resistance has highlighted the need fo...

  • Systematic Review
  • Open Access
30 Citations
8,333 Views
15 Pages

17 October 2023

Cell-based seasonal influenza vaccine viruses may more closely match recommended vaccine strains than egg-based options. We sought to evaluate the effectiveness of seasonal cell-based quadrivalent influenza vaccine (QIVc), as reported in the publishe...

  • Article
  • Open Access
24 Citations
6,023 Views
14 Pages

The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment

  • Giovanna Elisa Calabrò,
  • Sara Boccalini,
  • Donatella Panatto,
  • Caterina Rizzo and ,
  • Maria Luisa Di Pietro,
  • Fasika Molla Abreha,
  • Marco Ajelli,
  • Daniela Amicizia,
  • Angela Bechini and
  • Chiara de Waure
  • + 12 authors+ 7 authors

Background. The elderly, commonly defined as subjects aged ≥65 years, are among the at-risk subjects recommended for annual influenza vaccination in European countries. Currently, two new vaccines are available for this population: the MF59-adjuva...

(This article belongs to the Special Issue Influenza as a Problem of Public Health)
  • Article
  • Open Access
14 Citations
4,687 Views
18 Pages

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population

  • Anna Fochesato,
  • Sara Sottile,
  • Andrea Pugliese,
  • Sergio Márquez-Peláez and ,
  • Hector Toro-Diaz,
  • Ray Gani,
  • Piedad Alvarez and
  • Jesús Ruiz-Aragón
  • + 3 authors+ 0 author

20 August 2022

Standard-dose quadrivalent influenza vaccines (QIV) are designed to provide protection against all four influenza strains. Adjuvanted QIV (aQIV), indicated for individuals aged 65+ years, combines MF59® adjuvant (an oil-in-water emulsion of squal...

  • Article
  • Open Access
886 Views
20 Pages

Evaluation of Safety and Immunogenicity of High-Dose Quadrivalent Seasonal Influenza Split Vaccine: A Preclinical Study

  • Lanxin Jia,
  • Ran Qiu,
  • Jing Liu,
  • Bo Liu and ,
  • Xuanxuan Nian,
  • Yang Le,
  • Xixin Han,
  • Qingmei Zhang,
  • Xuedan Li and
  • Jiayou Zhang
  • + 9 authors+ 4 authors

Objectives: Seasonal influenza leads to substantial global morbidity and mortality, especially in adults aged 65 years and older, who present poor immune responses to standard-dose influenza vaccines. This study aimed to systematically evaluate the p...

(This article belongs to the Section Vaccine Advancement, Efficacy and Safety)
  • Article
  • Open Access
16 Citations
6,786 Views
16 Pages

Moderately Low Effectiveness of the Influenza Quadrivalent Vaccine: Potential Mismatch between Circulating Strains and Vaccine Strains

  • Maaweya E. Awadalla,
  • Haitham Alkadi,
  • Modhi Alarjani,
  • Abdullah E. Al-Anazi and ,
  • Mohanad A. Ibrahim,
  • Thamer Ahmad ALOhali,
  • Mushira Enani,
  • Wael Alturaiki and
  • Bandar Alosaimi
  • + 4 authors+ 0 author

31 May 2023

The annual seasonal influenza vaccination is the most effective way of preventing influenza illness and hospitalization. However, the effectiveness of influenza vaccines has always been controversial. Therefore, we investigated the ability of the qua...

(This article belongs to the Section Influenza Virus Vaccines)
  • Article
  • Open Access
9 Citations
5,112 Views
18 Pages

The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial

  • Lili Huang,
  • Guangfu Li,
  • Yuhui Zhang,
  • Xue Zhao and ,
  • Kai Wang,
  • Chunyu Jia,
  • Wei Zhang,
  • Jiebing Tan,
  • Xiaofen Chen and
  • Yaodong Zhang
  • + 12 authors+ 7 authors

26 April 2025

Background: Influenza is a serious contagious disease caused by influenza virus. It is particularly dangerous for children, potentially leading to severe and even fatal complications. The aim of this study was to evaluate the safety and immunogenicit...

(This article belongs to the Special Issue Human Immune Responses to Infection and Vaccination)
  • Case Report
  • Open Access
2 Citations
7,495 Views
6 Pages

Neuromyotonia with Central Nervous System Lesions following Quadrivalent Human Papilloma Virus Vaccination

  • Maryam Hatami,
  • Moritz Förster,
  • Vivien Weyers,
  • Saskia Räuber and ,
  • Sven G. Meuth and
  • David Kremer
  • + 1 author+ 0 author

16 July 2022

Neuromyotonia is a rare peripheral nerve hyperexcitability syndrome often associated with antibodies directed against contactin-associated protein-like 2 and leucine-rich, glioma inactivated 1. The quadrivalent human papilloma virus vaccine Gardasil&...

  • Article
  • Open Access
13 Citations
4,550 Views
10 Pages

28 September 2021

Mutations of the H3N2 vaccine strain during the egg-based vaccine manufacturing process partly explain the suboptimal effectiveness of traditional seasonal influenza vaccines. Cell-based influenza vaccines improve antigenic match and vaccine effectiv...

  • Article
  • Open Access
4 Citations
3,666 Views
15 Pages

Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge

  • Lindsay Hill-Batorski,
  • Yasuko Hatta,
  • Michael J. Moser,
  • Sally Sarawar and ,
  • Gabriele Neumann,
  • Yoshihiro Kawaoka and
  • Pamuk Bilsel
  • + 2 authors+ 0 author

4 April 2023

Current influenza vaccines demonstrate low vaccine efficacy, especially when the predominantly circulating strain and vaccine are mismatched. The novel influenza vaccine platform M2- or BM2-deficient single replication (M2SR and BM2SR) has been shown...

(This article belongs to the Special Issue Vaccines against Influenza Virus)
  • Systematic Review
  • Open Access
5 Citations
5,161 Views
11 Pages

Quadrivalent Vaccines for the Immunization of Adults against Influenza: A Systematic Review of Randomized Controlled Trials

  • Alice Mannocci,
  • Andrea Pellacchia,
  • Rossella Millevolte,
  • Manuela Chiavarini and
  • Chiara de Waure

Vaccination is the most effective intervention to prevent influenza. Adults at risk of complications are among the targets of the vaccination campaigns and can be vaccinated with different types of quadrivalent influenza vaccines (QIVs). In the light...

(This article belongs to the Special Issue Influenza as a Problem of Public Health)
  • Article
  • Open Access
8 Citations
5,184 Views
14 Pages

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina

  • Analia Urueña,
  • Paula Micone,
  • Cecilia Magneres,
  • Joaquin Mould-Quevedo and
  • Norberto Giglio

The burden of seasonal influenza disease in Argentina is considerable. The cost-effectiveness of trivalent (TIV) versus quadrivalent influenza vaccine (QIV) in Argentina was assessed. An age-stratified, static, decision-tree model compared the costs...

(This article belongs to the Section Influenza Virus Vaccines)
  • Review
  • Open Access
6 Citations
8,340 Views
14 Pages

Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis

  • Andrea Conti,
  • Gaia Broglia,
  • Chiara Sacchi,
  • Fabrizia Risi and ,
  • Francesco Barone-Adesi and
  • Massimiliano Panella
  • + 1 author+ 0 author

13 January 2023

Over the last decades, different quadrivalent antimeningococcal vaccine formulations (diphteria toxoid conjugate, MenACWY-D; tetanus toxoid conjugate, MenACWY-TT; CRM197 protein conjugate, MenACWY-CRM) have been developed. However, their availability...

  • Article
  • Open Access
21 Citations
7,048 Views
13 Pages

Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons

  • Constantina Boikos,
  • Ian McGovern,
  • Deborah Molrine,
  • Justin R. Ortiz and ,
  • Joan Puig-Barberà and
  • Mendel Haag
  • + 1 author+ 0 author

The adaptation of influenza seed viruses in egg culture can result in a variable antigenic vaccine match each season. The cell-based quadrivalent inactivated influenza vaccine (IIV4c) contains viruses grown in mammalian cell lines rather than eggs. I...

  • Article
  • Open Access
2 Citations
3,271 Views
14 Pages

Exploratory Study of the Phase IV Immunization Schedule of Quadrivalent Influenza Split-Virion Vaccine in Children Aged 3–8 Years

  • Xiaoyu Li,
  • Zengqiang Kou,
  • Ti Liu,
  • Wenjue An and ,
  • Wenqi An,
  • Wei Zhang,
  • Ke Zhang,
  • Jie Dong,
  • Jiangxuan Yu and
  • Chenyan Zhao
  • + 6 authors+ 1 author

18 March 2024

This study explored the optimum immunization schedule for the quadrivalent influenza split-virion vaccine containing influenza A strains (H1N1 and H3N2) and B lineage strains (Yamagata and Victoria) in children aged 3–8 years. The 652 participa...

  • Article
  • Open Access
8 Citations
4,078 Views
10 Pages

Outcomes in Pregnant Persons Immunized with a Cell-Based Quadrivalent Inactivated Influenza Vaccine: A Prospective Observational Cohort Study

  • Christopher Robinson,
  • Josephine Van Boxmeer,
  • Hugh Tilson,
  • Anthony Scialli and ,
  • John A. Vanchiere,
  • Ellis Ides,
  • Daphne Sawlwin,
  • Deborah Molrine,
  • Matthew Hohenboken and
  • Jessica D. Albano
  • + 6 authors+ 1 author

23 September 2022

Objective: To evaluate pregnancy and infant outcomes among persons immunized with a cell-based quadrivalent inactivated influenza vaccine (IIV4c) during routine pregnancy care. Design: Prospective observational cohort. Setting: US-based obstetrics/gy...

(This article belongs to the Special Issue Vaccination and Public Health)
  • Article
  • Open Access
26 Citations
3,418 Views
13 Pages

Induction of Broad Immunity against Invasive Salmonella Disease by a Quadrivalent Combination Salmonella MAPS Vaccine Targeting Salmonella Enterica Serovars Typhimurium, Enteritidis, Typhi, and Paratyphi A

  • Emily M. Boerth,
  • Joyce Gong,
  • Becky Roffler,
  • Claudette M. Thompson and ,
  • Boni Song,
  • Sasha F. Malley,
  • Angelika Hirsch,
  • Calman A. MacLennan,
  • Fan Zhang and
  • Ying-Jie Lu
  • + 6 authors+ 1 author

31 October 2023

Bloodstream infections in low- and middle-income countries (LMICs) are most frequently attributed to invasive Salmonella disease caused by four primary serovars of Salmonella enterica: Typhi, Paratyphi A, Typhimurium, and Enteritidis. We showed previ...

(This article belongs to the Section Vaccines Against Tropical and Other Infectious Diseases)
  • Article
  • Open Access
10 Citations
5,073 Views
12 Pages

Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort

  • Alltalents T. Murahwa,
  • Tinashe Mudzviti,
  • Racheal S. Dube Mandishora,
  • Takudzwa Chatindo and ,
  • Peace Chanetsa,
  • Margaret Pascoe,
  • Tinei Shamu,
  • Wisdom Basera,
  • Ruedi Luethy and
  • Anna-Lise Williamson
  • + 5 authors+ 0 author

22 January 2024

Background: Human papillomavirus (HPV) vaccination programs are a key intervention in protecting individuals against HPV-related disease. HIV1-infected individuals are at increased risk of HPV-associated cancers. This study was conducted to evaluate...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Brief Report
  • Open Access
1 Citations
2,912 Views
11 Pages

30 September 2025

Background: Children are at high risk of influenza infections and may spread the disease to vulnerable family members. Quadrivalent influenza vaccines (QIV) provide protection against four strains of influenza recommended annually by the World Health...

(This article belongs to the Section Influenza Virus Vaccines)
  • Brief Report
  • Open Access
2 Citations
3,284 Views
10 Pages

Four-Color Pseudovirus-Based Neutralization Assay: A Rapid Method for Evaluating Neutralizing Antibodies Against Quadrivalent Hand, Foot, and Mouth Disease Vaccine

  • Fan Gao,
  • Lingjie Xu,
  • Qian Wang,
  • Gang Wang and ,
  • Mingchen Liu,
  • Lu Li,
  • Qian He,
  • Xuanxuan Zhang,
  • Ying Wang and
  • Xing Wu
  • + 9 authors+ 4 authors

18 March 2025

Background/Objectives: Enterovirus 71 (EV71) and coxsackieviruses A16 (CA16), A10 (CA10), and A6 (CA6) are the primary pathogens that cause hand, foot, and mouth disease (HFMD). Currently, many manufacturers are developing bivalent, trivalent, and te...

(This article belongs to the Section Pathogens-Host Immune Boundaries)
  • Article
  • Open Access
6 Citations
3,370 Views
15 Pages

Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season

  • Maria Ganczak,
  • Paulina Dubiel,
  • Marzena Drozd-Dąbrowska,
  • Ewelina Hallmann-Szelińska and ,
  • Karol Szymański and
  • Lidia B. Brydak
  • + 1 author+ 0 author

The effects of immunization with subunit inactivated quadrivalent influenza vaccine (QIV) are not generally well assessed in the elderly Polish population. Therefore, this study evaluated vaccine-induced antibody response and its determinants. Method...

  • Article
  • Open Access
7 Citations
2,622 Views
15 Pages

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Administered Concomitantly with a 23-Valent Pneumococcal Polysaccharide Vaccine in Adults Aged 60 Years and Older

  • Zhongkui Zhu,
  • Jianwen Sun,
  • Yan Xie,
  • Xi Lu and ,
  • Wanqin Tang,
  • Yanwei Zhao,
  • Lu Shen,
  • Huaxian Liu,
  • Yang Yu and
  • Xiaoli Jiang
  • + 8 authors+ 3 authors

22 August 2024

The inactivated quadrivalent influenza vaccine (IIV4) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) have been administered for years and could be administered concomitantly if necessary. However, the immunogenicity and safety of the...

(This article belongs to the Section Influenza Virus Vaccines)
  • Article
  • Open Access
1,546 Views
15 Pages

A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil® in Healthy Volunteers Aged 15–35 Years

  • Erfan Pakatchian,
  • Minoo Mohraz,
  • Mohammad Taghavian,
  • Babak Javadimehr and ,
  • Hajar Mohammadi Barzelighi,
  • Majid Teymoori-Rad,
  • Mehrdad Ghodsi and
  • Zahra Naderi Saffar
  • + 3 authors+ 0 author

18 June 2026

Background/Objectives: Human papillomavirus (HPV) infection is the leading cause of cervical cancer and is associated with several anogenital and oropharyngeal malignancies. Although licensed HPV vaccines are highly effective, access remains limited...

(This article belongs to the Special Issue Recent Advances and Strategies for the Management of CIN and HPV Eradication Strategies for the Prevention of Uterine Cervical Cancer)
  • Article
  • Open Access
36 Citations
5,720 Views
12 Pages

Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years

  • Carmen Hidalgo-Tenorio,
  • Juan Pasquau,
  • Mohamed Omar-Mohamed,
  • Antonio Sampedro and ,
  • Miguel A. López-Ruz,
  • Javier López Hidalgo and
  • Jessica Ramírez-Taboada
  • + 2 authors+ 0 author

20 January 2021

Anal squamous cell carcinoma is the most frequent virus-related non-AIDS-defining neoplasia among HIV-infected individuals, especially MSM. The objectives of this study were to analyze the effectiveness of the quadrivalent HPV (qHPV) vaccine to preve...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Article
  • Open Access
7 Citations
4,077 Views
11 Pages

13 February 2023

Influenza infections impose a high burden of morbidity and mortality among older adults, at great cost to individuals and society. Enhanced influenza vaccines, which contain either an immune adjuvant or higher than normal doses of influenza virus ant...

  • Article
  • Open Access
2 Citations
6,347 Views
13 Pages

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Population Aged 3 Years and Older in Chile and the Philippines: A Phase 3, Non-Inferiority, Double-Blind, Randomized Controlled Clinical Trial

  • Wanqi Yang,
  • Pablo A. González,
  • Qianqian Xin,
  • Mari Rose De Los Reyes and ,
  • Ralph Elvi Villalobos,
  • Charissa Fay Corazon Borja-Tabora,
  • Nancy Nazaire Bermal,
  • Alexis M. Kalergis,
  • Dan Yu and
  • Jing Li
  • + 11 authors+ 6 authors

7 August 2024

Objectives: In this study, we aimed to evaluate the non-inferiority of a quadrivalent influenza vaccine (QIV) developed by Sinovac Biotech Co., Ltd. (Sinovac, Beijing, China) by comparing its immunogenicity and safety with a comparator QIV (Vaxigrip...

  • Article
  • Open Access
1 Citations
1,312 Views
17 Pages

Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6–35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial

  • Yoonsun Yoon,
  • Hye-Kyung Cho,
  • Ki Hwan Kim,
  • Su Eun Park and ,
  • Yae-Jean Kim,
  • Jina Lee,
  • Hwang Min Kim,
  • Nam Hee Kim,
  • Dae Sun Jo and
  • Yun-Kyung Kim
  • + 11 authors+ 6 authors

13 April 2026

Background: Influenza causes substantial morbidity in young children, particularly those aged 6–35 months. In this age group, optimisation of vaccine dose regimens remains important to ensure adequate immunogenicity while maintaining acceptable...

(This article belongs to the Special Issue Immunity to Influenza Viruses and Vaccines)
  • Article
  • Open Access
14 Citations
4,788 Views
14 Pages

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age

  • Airi Poder,
  • Janine Oberije,
  • Jay Meyer,
  • Peter Heymer and ,
  • Deborah Molrine,
  • Eve Versage,
  • Leah Isakov,
  • Qiuhong Zhang and
  • Matthew Hohenboken
  • + 4 authors+ 0 author

26 September 2023

Adults aged 50–64 years have a high incidence of symptomatic influenza associated with substantial disease and economic burden each year. We conducted a randomized, controlled trial to compare the immunogenicity and safety of an adjuvanted quad...

(This article belongs to the Section Influenza Virus Vaccines)
  • Article
  • Open Access
4 Citations
7,277 Views
13 Pages

Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France

  • Marc Paccalin,
  • Gaëtan Gavazzi,
  • Quentin Berkovitch,
  • Henri Leleu and ,
  • Romain Moreau,
  • Emanuele Ciglia,
  • Nansa Burlet and
  • Joaquin F. Mould-Quevedo
  • + 3 authors+ 0 author

Background: In France, influenza accounts for an average of over one million consultations with GPs, 20,000 hospitalizations, and 9000 deaths per year, particularly among the over-65s. This study evaluates the cost-effectiveness of the adjuvanted qua...

(This article belongs to the Special Issue Influenza Virus Vaccines and Vaccination)
  • Article
  • Open Access
24 Citations
6,450 Views
18 Pages

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States

  • Girishanthy Krishnarajah,
  • Victoria Divino,
  • Maarten J. Postma,
  • Stephen I. Pelton and ,
  • Vamshi Ruthwik Anupindi,
  • Mitch DeKoven and
  • Joaquin Mould-Quevedo
  • + 2 authors+ 0 author

23 January 2021

Non-egg-based influenza vaccines eliminate the potential for egg-adapted mutations and potentially increase vaccine effectiveness. This retrospective study compared hospitalizations/emergency room (ER) visits and all-cause annualized healthcare costs...

(This article belongs to the Special Issue Health Economics of Vaccines)
  • Article
  • Open Access
22 Citations
5,961 Views
12 Pages

23 January 2022

Influenza is a contagious respiratory disease that causes severe illness and death, particularly in elderly populations. Two enhanced formulations of quadrivalent influenza vaccine (QIV) are available in Spain. Adjuvanted QIV (aQIV) is available for...

  • Article
  • Open Access
855 Views
23 Pages

Evolution of National Influenza Vaccine Platform: From Comprehensive Preclinical Safety Validation of Trivalent Influenza Vaccine to Streamlined Immunogenicity of Quadrivalent Formulation

  • Luka Dragačević,
  • Veljko Blagojević,
  • Marko Vasić,
  • Rajna Minić and ,
  • Ivana Ćuruvija,
  • Ivana Prijić,
  • Raisa Petrović,
  • Darko Rogić and
  • Irena Živković
  • + 4 authors+ 0 author

Background: The Global Action Plan for Influenza Vaccines, launched by the World Health Organization in 2006, aimed to expand global manufacturing capacity, ensure equitable access to influenza vaccines, and reduce global vaccine shortages. The Insti...

(This article belongs to the Special Issue Vaccine Development for Influenza Virus: 2nd Edition)
  • Article
  • Open Access
12 Citations
3,608 Views
12 Pages

A Prospective Study Investigating the Impact of Obesity on the Immune Response to the Quadrivalent Influenza Vaccine in Children and Adolescents

  • Michelle Clarke,
  • Suja M. Mathew,
  • Lynne C. Giles,
  • Alexia S. Pena and ,
  • Ian G. Barr,
  • Peter C. Richmond and
  • Helen S. Marshall
  • + 2 authors+ 0 author

29 April 2022

Obesity can increase the severity of influenza infection. Data are limited regarding immune responses to influenza vaccination in obese children. We aimed to investigate the impact of obesity on quadrivalent influenza vaccine responses in children. C...

(This article belongs to the Topic Strategies for Prevention and Control of Influenza)
  • Article
  • Open Access
9 Citations
3,440 Views
11 Pages

A Prospective Cohort Study on Pregnancy Outcomes of Persons Immunized with a Seasonal Quadrivalent Inactivated Influenza Vaccine during Pregnancy

  • Christopher Robinson,
  • Janine Oberye,
  • Josephine van Boxmeer,
  • Jessica D. Albano and ,
  • Hugh Tilson,
  • Anthony Scialli,
  • John A. Vanchiere,
  • Ellis Ides,
  • Daphne Sawlwin and
  • Jonathan Edelman
  • + 6 authors+ 1 author

21 September 2022

This US-based, prospective observational cohort study evaluated the safety of a quadrivalent inactivated influenza vaccine (IIV4; Afluria Quadrivalent) in pregnant persons immunized over four influenza seasons between 2017 and 2021. Pregnancy outcome...

(This article belongs to the Special Issue Vaccination and Public Health)
  • Review
  • Open Access
6 Citations
7,314 Views
17 Pages

15 October 2023

Cell-based manufacturing of seasonal influenza vaccines eliminates the risk of egg-adaptation of candidate vaccine viruses, potentially increasing vaccine effectiveness (VE). We present an overview of published data reporting the VE and cost-effectiv...

(This article belongs to the Section Influenza Virus Vaccines)
  • Review
  • Open Access
25 Citations
15,080 Views
19 Pages

Since the mid-1980s, two lineages of influenza B viruses have been distinguished. These can co-circulate, limiting the protection provided by inactivated trivalent influenza vaccines (TIVs). This has prompted efforts to formulate quadrivalent influen...

  • Article
  • Open Access
9 Citations
5,216 Views
15 Pages

17 June 2024

Influenza viruses can cause highly infectious respiratory diseases, posing noteworthy epidemic and pandemic threats. Vaccination is the most cost-effective intervention to prevent influenza and its complications. However, reliance on embryonic chicke...

(This article belongs to the Special Issue Advances in Influenza Virus Vaccines)
  • Article
  • Open Access
3 Citations
3,841 Views
16 Pages

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population

  • Diana Tavares,
  • Helena Mouriño,
  • Cristina Antón Rodríguez and
  • Carlos Martín Saborido

9 August 2022

Background: quadrivalent inactivated vaccine (QIV) has replaced trivalent inactivated vaccine (TIV). In Portugal, TIV is free of charge for risk groups, including older adults (≥65 years old). In its turn, QIV—which provides broader protecti...

(This article belongs to the Section Vaccines and Public Health)
  • Article
  • Open Access
18 Citations
9,014 Views
21 Pages

Cost-Effectiveness of Vaccination of Older Adults with an MF59®-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden

  • Jorge Jacob,
  • Tor Biering-Sørensen,
  • Lars Holger Ehlers,
  • Christina H. Edwards and ,
  • Kristin Greve-Isdahl Mohn,
  • Anna Nilsson,
  • Jonas Hjelmgren,
  • Wenkang Ma,
  • Yuvraj Sharma and
  • Joaquin Mould-Quevedo
  • + 6 authors+ 1 author

29 March 2023

Individuals aged 65 years and above are at increased risk of complications and death from influenza compared with any other age group. Enhanced vaccines, as the MF59®-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose quadrivalent...

(This article belongs to the Section Vaccines and Public Health)
  • Article
  • Open Access
1 Citations
1,725 Views
24 Pages

Immunogenic Properties and Safety of a Quadrivalent Inactivated Subunit Adjuvanted Influenza Vaccine in Adults Aged 18 to 85 Years at the End of the COVID-19 Pandemic in the 2022–2023 Season

  • Mikhail P. Kostinov,
  • Aristitsa M. Kostinova,
  • Sofia Iushkova,
  • Lilia Gladkova and ,
  • Anna Vlasenko,
  • Yulia Dagil,
  • Maria Kvasova,
  • Anastasia Kameleva,
  • Anastasia Kachnova and
  • Anton M. Kostinov
  • + 12 authors+ 7 authors

14 February 2026

Background: SARS-CoV-2 infection has raised concerns about altered immune responses, creating a need to evaluate influenza vaccine performance in the post-COVID period. This study aimed to compare the immunogenicity and safety of a quadrivalent inact...

(This article belongs to the Section Vaccine Advancement, Efficacy and Safety)
  • Article
  • Open Access
10 Citations
3,638 Views
12 Pages

Background: Enhanced vaccines (e.g., containing adjuvants) have shown increased immunogenicity and effectiveness in older adults, who often respond sub-optimally to conventional influenza vaccines. In this study, we evaluated the cost-effectiveness o...

(This article belongs to the Section Influenza Virus Vaccines)
  • Systematic Review
  • Open Access
3 Citations
3,372 Views
16 Pages

Influenza vaccination is an important public health measure that can reduce disease burden, especially among older persons (those aged 65 and over) who have weaker immune systems. Evidence suggests enhanced vaccines, including adjuvanted quadrivalent...

  • Article
  • Open Access
9 Citations
4,565 Views
16 Pages

Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency

  • Mikhail P. Kostinov,
  • Elena A. Latysheva,
  • Aristitsa M. Kostinova,
  • Nelly K. Akhmatova and ,
  • Tatyana V. Latysheva,
  • Anna E. Vlasenko,
  • Yulia A. Dagil,
  • Ekaterina A. Khromova and
  • Valentina B. Polichshuk
  • + 4 authors+ 0 author

2 November 2020

Background. Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice. Methods. In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvan...

(This article belongs to the Special Issue Immune Responses to Influenza Virus Antigens)
  • Article
  • Open Access
19 Citations
5,246 Views
17 Pages

Balanced Cellular and Humoral Immune Responses Targeting Multiple Antigens in Adults Receiving a Quadrivalent Inactivated Influenza Vaccine

  • Esther Dawen Yu,
  • Alba Grifoni,
  • Aaron Sutherland,
  • Hannah Voic and ,
  • Eric Wang,
  • April Frazier,
  • Natalia Jimenez-Truque,
  • Sandra Yoder,
  • Sabrina Welsh and
  • Ricardo da Silva Antunes
  • + 9 authors+ 4 authors

23 April 2021

The role of T cell immunity has been acknowledged in recent vaccine development and evaluation. We tested the humoral and cellular immune responses to Flucelvax®, a quadrivalent inactivated seasonal influenza vaccine containing two influenza A (H1N1...

  • Article
  • Open Access
2 Citations
3,134 Views
14 Pages

22 October 2024

Imidazo-fused diazaborines, which serve as intermediary structures somewhat alongside benzene and borazine, had been of particular interest to Dewar and Snyder more than 60 years ago. To this end, Dewar utilised his ‘π-complex theory’s...

  • Article
  • Open Access
1 Citations
1,987 Views
20 Pages

Preclinical Assessment of a New Virus-like Particle-Based Quadrivalent Human Papillomavirus Vaccine in Animal Models

  • Hajar Mohammadi Barzelighi,
  • Zahra Naderi Saffar,
  • Erfan Pakatchian,
  • Mohammad Taqavian and ,
  • Babak Javadimehr,
  • Mansooreh Safaeian,
  • Payam Abbaszadeh and
  • Hasan Jalili
  • + 3 authors+ 0 author

5 January 2026

Background: A quadrivalent HPV vaccine (BPV) has been developed to prevent diseases caused by HPV types 6, 11, 16, and 18 for the first time in Iran. The BPV is composed of the papillomavirus major capsid protein L1, which serves as the primary targe...

(This article belongs to the Section Human Papillomavirus Vaccines)
  • Article
  • Open Access
6 Citations
6,704 Views
14 Pages

The Effectiveness of Four Quadrivalent, Inactivated Influenza Vaccines Administered Alone or in Combination with Pneumococcal and/or SARS-CoV-2 Vaccines: A Population-Wide Cohort Study

  • Cecilia Acuti Martellucci,
  • Annalisa Rosso,
  • Enrico Zauli,
  • Alessandro Bianconi and ,
  • Matteo Fiore,
  • Graziella Soldato,
  • Patrizia Marani Toro,
  • Marco De Benedictis,
  • Graziano Di Marco and
  • Lamberto Manzoli
  • + 8 authors+ 3 authors

13 March 2025

Background: Several influenza vaccine formulations are available, including adjuvanted, high-dose, trivalent, and quadrivalent vaccines, and direct, comparative evidence on the relative effectiveness is limited. Real-life data on the potential impact...

(This article belongs to the Section Vaccine Advancement, Efficacy and Safety)
  • Article
  • Open Access
1 Citations
2,800 Views
11 Pages

Immunogenicity and Antibody Persistence of the Inactivated Quadrivalent Influenza Vaccine in Pediatric Patients Post-Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation Versus Healthy Controls

  • Mi Yeon Hur,
  • Kyu Ri Kang,
  • Ye Ji Kim,
  • Yoon Kyung Cho and ,
  • Jae Wook Lee,
  • Nack-Gyun Chung,
  • Bin Cho,
  • Dae Chul Jeong,
  • Jin Han Kang and
  • Hyun Mi Kang
  • + 5 authors+ 0 author

28 October 2024

Pediatric patients who have undergone hematopoietic stem cell transplantation (HSCT) or chemotherapy are at increased risk for severe influenza complications, necessitating annual vaccination. This study evaluated the immunogenicity and antibody pers...

of 4